Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05888532

64Cu-GRIP B in Patients With Advanced Malignancies

A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Solid Tumor Metastatic Castration-resistant Prostate Cancer Prostate Cancer Renal Cancer Solid Tumor, Adult Urethral Cancer

Interventions Copper-64 labeled Granzyme B (64Cu-GRIP B) Positron Emission Tomography (PET)

Updated 5 times since 2023 Last updated: Jan 25, 2025 Started: May 25, 2023 Primary completion: Dec 31, 2026 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Solid Tumor and Metastatic Castration-resistant Prostate Cancer and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Feb 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Rahul Aggarwal
U.S. Army Medical Research Acquisition Activity

Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States